CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

Authors :: Yilun Deng
Aravind Kancharla
Myrna Garcia
Deyi Zhang
Niannian Ji
Neelam Mukherjee
Karen Wheeler
Tyler J Curiel
Robert S Svatek
Ryan Michael Reyes
Harshita B Gupta
Alvaro S Padron
Chenghao Zhang
Anand V R Kornepati
Onur Boyman
Jose R Conejo-Garcia
Source :: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Publication Year :: 2021
Publisher :: BMJ Publishing Group, 2021.
Abstract: Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools